In The News
NAB super trustee entitled to pay adviser commissions, class action judge says
Coles, Woolworths say price increases were genuine, and so were the discounts
Start-up denies ex-Fortescue employees developed green iron process on company dime
In class action defence, Toyota says ‘defeat device’ used to protect engines
Hamilton Locke loses challenge to Sydney law firm’s trade mark
Solve My Debt Now to admit liability in ASIC proceedings
Maddocks lures leading competition lawyer from Johnson Winter Slattery
Builder and developer off hook for $3M in fire safety repairs
Property investment firm found negligent for Perth development promises
Class action against NAB super fund trustee fails
Please login to bookmarkClose

An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug  was wrongly granted.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au